Journal ArticleDOI
Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia
Bruno Speck,Mortimer M. Bortin,Richard Champlin,J.M. Goldman,Roger H. Herzig,Philip B. McGlave,Hans A. Messner,Roy S. Weiner,Alfred A. Rimm +8 more
TLDR
It is demonstrated that long-term disease-free survival in CML can be achieved with bone-marrow transplantation, and best results were obtained in patients transplanted during chronic phase of the disease.About:
This article is published in The Lancet.The article was published on 1984-03-24. It has received 242 citations till now. The article focuses on the topics: Transplantation & Blastic Phase.read more
Citations
More filters
Journal ArticleDOI
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
Hagop M. Kantarjian,Charles L. Sawyers,Andreas Hochhaus,François Guilhot,Charles A. Schiffer,Carlo Gambacorti-Passerini,Dietger Niederwieser,Debra Resta,Renaud Capdeville,Ulrike Zoellner,Moshe Talpaz,Brian J. Druker +11 more
TL;DR: Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed, and CML had not progressed to the accelerated or blast phases after a median follow-up of 18 months.
Journal ArticleDOI
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Rainer Storb,H. Joachim Deeg,John Whitehead,Frederick R. Appelbaum,Patrick G. Beatty,William I. Bensinger,C. Dean Buckner,Reginald A. Clift,Kristine Doney,Vernon T. Farewell,J. D. Hansen,Roger Hill,Lawrence G. Lum,Paul J. Martin,Robert W. McGuffin,Jean E. Sanders,Patricia S. Stewart,Keith M. Sullivan,Robert P. Witherspoon,Gary Yee,E. Donnall Thomas +20 more
TL;DR: It is concluded that the combination of methotrexate and cyclosporine is superior to cyclOSporine alone in the prevention of acute graft versus host disease after marrow transplantation for leukemia, and that this therapy may have a beneficial effect on long-term survival.
Journal ArticleDOI
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Robert H. Collins,Ofer Shpilberg,William R. Drobyski,D L Porter,Sergio Giralt,R Champlin,S A Goodman,S N Wolff,W Hu,Catherine M. Verfaillie,Alan F. List,William S. Dalton,N Ognoskie,Angela Chetrit,Joseph H. Antin,John Nemunaitis +15 more
TL;DR: DLI results in complete remissions in a high percentage of patients with relapsed chronic-phase CML, and acute and chronic GVHD post-DLI were highly correlated with disease response (P < .00001).
Journal ArticleDOI
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani,Jorge E. Cortes,Fabrizio Pane,Dietger Niederwieser,Giuseppe Saglio,Jane F. Apperley,Francisco Cervantes,Michael W. Deininger,Alois Gratwohl,François Guilhot,Andreas Hochhaus,Mary M. Horowitz,Timothy P. Hughes,Hagop M. Kantarjian,Richard A. Larson,Jerald P. Radich,Bengt Simonsson,Richard T. Silver,John M. Goldman,Rüdiger Hehlmann +19 more
TL;DR: Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.
Journal ArticleDOI
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers,Andreas Hochhaus,Eric J. Feldman,John M. Goldman,Carole B. Miller,Oliver G. Ottmann,Charles A. Schiffer,Moshe Talpaz,François Guilhot,Michael W. Deininger,Thomas M. Fischer,S. O'Brien,Richard Stone,Carlo Gambacorti-Passerini,Nigel H. Russell,Jose J. Reiffers,Thomas C. Shea,Bernard Chapuis,Steven Coutre,Sante Tura,Enrica Morra,Richard A. Larson,Alan Saven,Christian Peschel,Alois Gratwohl,Franco Mandelli,Monique Ben-Am,Insa Gathmann,Renaud Capdeville,Ronald Paquette,Brian J. Druker +30 more
TL;DR: It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.
References
More filters
Journal ArticleDOI
Maximum utilization of the life table method in analyzing survival
Sidney J. Cutler,Fred Ederer +1 more
TL;DR: Acceptance of survival as a criterion for measuring the effectiveness of cancer therapy is attested to by the very large number of papers published every year reporting on the survival experience of cancer patients.
Journal ArticleDOI
A computer program for comparing K samples with right-censored data
TL;DR: A nonparametric test for testing whether the K samples, on hand, are from the same distribution is calculated, an extension of the Kruskal-Wallis test, which can be used in those cases where the censoring has been applied in similar manner in all the samples.
Journal ArticleDOI
Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.
R. L. Powles,H.M. Clink,D. Spence,G.R. Morgenstern,J.G. Watson,Peter Selby,M. Woods,A. Barrett,B. Jameson,John P. Sloane,Sylvia D. Lawler,H.E.M. Kay,D.N. Lawson,T. J. McElwain,P Alexander +14 more
TL;DR: Several toxic effects of cyclosporin A have been observed but they are mostly reversible and no second malignant neoplasm has developed.
Journal ArticleDOI
Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia.
Karl G. Blume,Ernest Beutler,Bross Kj,Ram K. Chillar,Ellington Ob,Fahey Jl,Farbstein Mj,Stephen J. Forman,G M Schmidt,Edward P. Scott,Spruce We,Mark A. Turner,Jeffrey L. Wolf +12 more
TL;DR: High-dose chemotherapy and total-body irradiation followed by allogeneic bone-marrow transplantation performed during complete or partial remission can produce long-term remission of acute leukemia.
Related Papers (5)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more